Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

8 results
2:45 PM, May 12, 2017  |  BioCentury | Strategy

Vertical vision

eye disease. The drug is an eye drop formulation of a small molecule integrin beta(2) (LFA-1
MAC-1; CD18) antagonist. LFA-1 is a cell surface protein found on leukocytes that binds with intercellular …
12:00 AM, Jul 21, 2014  |  BioCentury | Strategy

AbbVie's plan B

mixed results. The compound is an eye drop formulation of a small molecule integrin beta(2) (LFA-1
12:00 AM, Apr 01, 2013  |  BioCentury | Strategy

Shire sees opportunity

deal provides lifitegrast ( SAR 1118 ), an eye drop formulation of a small molecule LFA-1
Phase III results, he said, demonstrate "a clear drug effect." Lifitegrast blocks the interaction of LFA-1
12:00 AM, Oct 23, 2006  |  BioCentury | Strategy

Icos chronicles

acquired ICOS's stake in the JV in April 2003.O. June 2003 - Reacquires rights to LFA-1
12:00 AM, Oct 23, 2006  |  BioCentury | Strategy

Share not, want not

with seven preclinical programs to treat cancer and inflammatory diseases. The two most advanced, an LFA-1
12:00 AM, Jun 30, 2003  |  BioCentury | Strategy

Merging is the easy part

this month, BGEN ended its only other later-stage partnership when the company returned rights to LFA-1
12:00 AM, Sep 03, 2002  |  BioCentury | Strategy

Biogen's pipeline

adenosine A1 antagonist Congestive heart failure Ph II Lymphotoxin beta receptor Autoimmune diseases Ph I LFA-1
12:00 AM, Mar 18, 2002  |  BioCentury | Strategy

Biogen clinical pipeline

antagonist Phase II Congestive heart failure CV Therap Lymphotoxin Phase I Autoimmune beta receptor diseases LFA-1